← Back to all trials
Recruiting
NCT06828796
Early Use of Tacrolimus in HLA-Mismatched Haploidentical Allogeneic Hematopoietic Transplantation With Post-Transplant Cyclophosphamide
Conditions: Hematologic Disease and Disorders, Hematopoietic Cell Transplant
Sex: All
Ages: 18 Years – 80 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 20
Sponsor: Northside Hospital, Inc.
Location: Northside Hospital Atlanta Georgia
Summary
To evalute the safety and efficacy in reducing Cytokine Release Syndrome after hematopoietic stem cell transplantation by introducing immunosuppression earlier in the transplant process
Eligibility Criteria
Inclusion Criteria:
* Availability of a 5/10-8/10 mismatched (HLA-A, B, DR) haploidentical related donor with a negative HLA cross-match in the host vs. graft direction and willing to provide peripheral blood stem cells
* Karnofsky status \>/= 70%
* Hematologic malignancy requiring allogeneic transplantation
* First allogeneic transplant only. Prior autologous transplant is allowed.
Exclusion Criteria:
* Poor cardiac function: LVEF \
Source: ClinicalTrials.gov (NCT06828796). StuddyBuddy aggregates publicly available trial information.
